Late antibody-mediated rejection after ABO-incompatible kidney transplantation during Gram-negative sepsis

被引:3
|
作者
de Weerd, Annelies [1 ]
Vonk, Alieke [2 ]
van der Hoek, Hans [3 ]
van Groningen, Marian [4 ]
Weimar, Willem [1 ]
Betjes, Michiel [1 ]
van Agteren, Madelon [1 ]
机构
[1] Erasmus MC, Dept Nephrol, NL-3000 CA Rotterdam, Netherlands
[2] Erasmus MC, Dept Microbiol & Infect Dis, NL-3000 CA Rotterdam, Netherlands
[3] Erasmus MC, Dept Hematol, NL-3000 CA Rotterdam, Netherlands
[4] Erasmus MC, Dept Pathol, NL-3000 CA Rotterdam, Netherlands
来源
BMC NEPHROLOGY | 2014年 / 15卷
关键词
ABO-incompatible kidney transplantation; Serratia marcescens; Antibody-mediated rejection; Bacteremia-induced anti-ABO antibodies; POSITIVE CROSS-MATCH; RENAL-TRANSPLANTATION; DONOR; BACTERIA; ACCOMMODATION; DETERIORATION; ALLOGRAFTS; TITER; RISK;
D O I
10.1186/1471-2369-15-31
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: The major challenge in ABO-incompatible transplantation is to minimize antibody-mediated rejection. Effective reduction of the anti-ABO blood group antibodies at the time of transplantation has made ABO-incompatible kidney transplantation a growing practice in our hospital and in centers worldwide. ABO antibodies result from contact with A-and B-like antigens in the intestines via nutrients and bacteria. We demonstrate a patient with fulminant antibody-mediated rejection late after ABO-incompatible kidney transplantation, whose anti-A antibody titers rose dramatically following Serratia marcescens sepsis. Case presentation: A 58-year-old woman underwent an ABO-incompatible kidney transplantation for end-stage renal disease secondary to autosomal dominant polycystic kidney disease. It concerned a blood group A1 to O donation. Pre-desensitization titers were 64 for anti-blood group A IgM and 32 for anti-blood group A IgG titers. Desensitization treatment consisted of rituximab, tacrolimus, mycophenolate mofetil, corticosteroids, immunoadsorption and intravenous immunoglobulines. She was readmitted to our hospital 11 weeks after transplantation for S. marcescens urosepsis. Her anti-A IgM titer rose to >5000 and she developed a fulminant antibody-mediated rejection. We hypothesized that the (overwhelming) presence in the blood of S. marcescens stimulated anti-A antibody formation, as S. marcescens might share epitopes with blood group A antigen. Unfortunately we could not demonstrate interaction between blood group A and S. marcescens in incubation experiments. Conclusion: Two features of this post-transplant course are remarkably different from other reports of acute rejection in ABO-incompatible kidney transplantation: first, the late occurrence 12 weeks after kidney transplantation and second, the very high anti-A IgM titers (>5000), suggesting recent boosting of anti-A antibody formation by S. marcescens.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Late antibody-mediated rejection after ABO-incompatible kidney transplantation during Gram-negative sepsis
    Annelies de Weerd
    Alieke Vonk
    Hans van der Hoek
    Marian van Groningen
    Willem Weimar
    Michiel Betjes
    Madelon van Agteren
    BMC Nephrology, 15
  • [2] Daratumumab for treatment of antibody-mediated rejection after ABO-incompatible kidney transplantation
    Spica, Davide
    Junker, Till
    Dickenmann, Michael
    Schaub, Stefan
    Steiger, Jurg
    Rufli, Tanja
    Halter, Jorg
    Hopfer, Helmut
    Holbro, Andreas
    Hirt-Minkowski, Patricia
    SWISS MEDICAL WEEKLY, 2019, : 14S - 15S
  • [3] Daratumumab for Treatment of Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation
    Spica, Davide
    Junker, Till
    Dickenmann, Michael
    Schaub, Stefan
    Steiger, Jurg
    Rufli, Tanja
    Halter, Jorg
    Hopfer, Helmut
    Holbro, Andreas
    Hirt-Minkowski, Patricia
    CASE REPORTS IN NEPHROLOGY AND DIALYSIS, 2019, 9 (03): : 149 - 157
  • [4] REVERSAL OF REFRACTORY ANTIBODY-MEDIATED REJECTION IN ABO-INCOMPATIBLE KIDNEY TRANSPLANTATION BY ECULIZUMAB
    Morath, C.
    Kirschfink, M.
    Waldherr, R.
    Becker, L. E.
    Kihm, L. P.
    Schaier, M.
    Schwenger, V.
    Schmidt, J.
    Hohenfellner, M.
    Leo, A.
    Opelz, G.
    Suesal, C.
    Zeier, M.
    TRANSPLANT INTERNATIONAL, 2011, 24 : 34 - 34
  • [5] ABO Antibody Titer and Risk of Antibody-Mediated Rejection in ABO-Incompatible Renal Transplantation
    Tobian, A. A. R.
    Shirey, R. S.
    Montgomery, R. A.
    Cai, W.
    Haas, M.
    Ness, P. M.
    King, K. E.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (05) : 1247 - 1253
  • [6] The Significance of Microvascular Inflammation in Antibody-Mediated Rejection in ABO-Incompatible Kidney Transplantation.
    Ishihara, H.
    Ishida, H.
    Unagami, K.
    Hirai, T.
    Okumi, M.
    Omoto, K.
    Shimizu, T.
    Tanabe, K.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 : 601 - 602
  • [7] IMPACT OF INFECTIOUS COMPLICATIONS ON ANTIBODY-MEDIATED REJECTION AFTER ABO-INCOMPATIBLE KIDNEY TRANSPLANTATIONS
    Kwon, Hyunwook
    Kim, Young Hoon
    Kim, Dong Hyun
    Ko, Youngmin
    Jung, Joo Hee
    Han, Duck Jong
    TRANSPLANT INTERNATIONAL, 2019, 32 : 395 - 395
  • [8] Association between response to rituximab and antibody-mediated rejection in ABO-incompatible living kidney transplantation
    Maenosono, Ryoichi
    Unagami, Kohei
    Kakuta, Yoichi
    Furusawa, Miyuki
    Okumi, Masayoshi
    Azuma, Haruhito
    Ishida, Hideki
    Tanabe, Kazunari
    INTERNATIONAL JOURNAL OF UROLOGY, 2019, 26 (12) : 1114 - 1120
  • [9] Acute antibody-mediated rejection after ABO-incompatible kidney transplantation treated successfully with antigen-specific immunoadsorption
    Just, Soren Andreas
    Marcussen, Niels
    Sprogoe, Ulrik
    Koefoed-Nielsen, Pernille
    Bistrup, Claus
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2010, 25 (01) : 310 - 313
  • [10] Association between Response to Rituximab and Risk of Antibody-Mediated Rejection in ABO-Incompatible Living Kidney Transplantation
    Kakuta, Y.
    Okumi, M.
    Kanzawa, T.
    Unagami, K.
    Ishida, H.
    Tanabe, K.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 898 - 898